

## Special Issue

# Pathophysiology, Risk Factors and Management in HFpEF Patients with Comorbidities

### Message from the Guest Editors

Heart failure with preserved ejection fraction (HFpEF) is a highly complex clinical syndrome, representing the most common type of heart failure. It is often characterized by a high prevalence of coexisting comorbidities, such as atrial fibrillation, diabetes mellitus, hypertension and obesity. HFpEF patients with co-morbidities have higher risks of worse clinical outcomes in clinical settings. Therefore, the early identification of those HFpEF patients at a high risk of comorbidities may prompt the initiation of prevention management, and thus improve prognosis. In this research topic, we would like to create a forum for discussion on the current understanding of the pathophysiology, risk factors and management of HFpEF patients with co-morbidities. We welcome submissions of original articles, reviews covering, but not limited to, the following subtopics:

- The current understanding of the pathophysiology (especially molecular mechanisms) of comorbidities in HFpEF.
- Risk factors associated with disease development, or risk models for predicting comorbidities in HFpEF.

---

### Guest Editors

Dr. Wengen Zhu

Dr. Jianyong Ma

Dr. Xiao Liu

---

### Deadline for manuscript submissions

closed (31 August 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/166790](https://mdpi.com/si/166790)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).